by Cassie Arnold | Jan 30, 2017 | Biotech Finance
2017: Above Average VC Investment, Maybe a Record for M&A I’m breaking with tradition and publishing my own predictions for the life sciences sector in 2017. I do research like this all the time for clients, but I never put it out under my own name. I’m taking...
by Cassie Arnold | Apr 5, 2016 | Biotech Finance
In Praise of the $1,000 Pill There has been a lot of ink spilt in my industry in the past year about the astronomic rise in drug prices. The exploits of a boyish former-hedge fund manager who raised the price of a drug 5,000% when he was running Turing Pharmaceuticals...
by Cassie Arnold | Oct 19, 2015 | Biotech Finance
Bubble Trouble I work with the life sciences industry, and for those of us who have defended the potential of the chronically loss-making sector for decades, the last few years have been heady times. Not only has the sector been attracting capital at record rates, it...
